Logotype for Carbios SAS

Carbios (ALCRB) H1 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Carbios SAS

H1 2024 earnings summary

19 Jan, 2026

Executive summary

  • Construction of the world's first industrial PET enzymatic biorecycling plant in Longlaville, France, is progressing on schedule, targeting commissioning in late 2025 and production in 2026.

  • Focus on enzymatic recycling technologies for PET and PLA, supported by a strong R&D and patent portfolio (59 patent families, 150+ employees).

  • Three revenue streams: licensing PET biorecycling, PLA biodegradation, and future polymer innovations.

  • Strategic partnerships and licensing LOIs with major brands (L'Oréal, PepsiCo, Nestlé Waters), industrial partners (Indorama, Desmet, Novonesis), and international groups (Zhink Group, SASA, FCC Environment UK).

  • Several feedstock supply agreements and MOUs secured for the Longlaville plant, including with Landbell Group, Hündgen, TOMRA Textiles, and Nouvelles Fibres Textiles.

Financial highlights

  • Cash position at June 30, 2024, was €120M, with €23.4M in term deposits and €42.5M in expected public funding; total cash and term deposits stood at €144M, down from €192M at year-end 2023.

  • H1 2024 loss from operations was €20M, with a total H1 loss of €80M; net loss was €18.1M, up from €13.7M in H1 2023.

  • R&D expenses increased to €11.8M, with net R&D expenses at €8.2M after subsidies.

  • Financial income improved due to capital increase, deposit returns, and interest on money market investments.

  • Sales and marketing expenses rose to €4.3M, and general & administrative expenses to €7.6M, mainly due to ERP implementation and staff costs.

Outlook and guidance

  • Longlaville plant expected to generate over €150M revenue and over €50M EBITDA at full ramp-up, with IRR expected above 20% and EBITDA margin above 40%.

  • Licensing model to provide upfront fees, recurring enzyme revenue share, and premium royalties.

  • Break-even expected in 2027, driven by plant operations and licensing income.

  • PLA biodegradation commercial activity to start end of 2024 or early 2025.

  • Construction and recruitment for the plant will continue through the second half of 2024.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more